Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PTPRF-PHF20

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PTPRF-PHF20
	FusionPDB ID: 70386
	FusionGDB2.0 ID: 70386
		Hgene	Tgene
	Gene symbol	PTPRF	PHF20
	Gene ID	5792	51230
	Gene name	protein tyrosine phosphatase receptor type F	PHD finger protein 20
	Synonyms	BNAH2\|LAR	C20orf104\|GLEA2\|HCA58\|NZF\|TDRD20A\|TZP
	Cytomap	1p34.2	20q11.22-q11.23
	Type of gene	protein-coding	protein-coding
	Description	receptor-type tyrosine-protein phosphatase FLCA-homologleukocyte antigen-related (LAR) PTP receptorleukocyte antigen-related tyrosine phosphataseleukocyte common antigen relatedprotein tyrosine phosphatase, receptor type, F polypeptidereceptor-linke	PHD finger protein 20glioma-expressed antigen 2hepatocellular carcinoma-associated antigen 58novel zinc finger proteintranscription factor TZPtudor domain containing 20A
	Modification date	20200313	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000359947, ENST00000372413, ENST00000372414, ENST00000438120, ENST00000422171, ENST00000496447,	ENST00000439301, ENST00000481202, ENST00000374012,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	22 X 15 X 12=3960	26 X 25 X 15=9750
	# samples	24	32
	** MAII score	log2(24/3960*10)=-4.04439411935845 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(32/9750*10)=-4.92925840863697 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PTPRF [Title/Abstract] AND PHF20 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PTPRF [Title/Abstract] AND PHF20 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PTPRF(44044591)-PHF20(34487292), # samples:2
Anticipated loss of major functional domain due to fusion event.	PTPRF-PHF20 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PTPRF-PHF20 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PTPRF-PHF20 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PTPRF-PHF20 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	PTPRF	GO:0099560	synaptic membrane adhesion	26321637
Tgene	PHF20	GO:0043981	histone H4-K5 acetylation	20018852
Tgene	PHF20	GO:0043982	histone H4-K8 acetylation	20018852
Tgene	PHF20	GO:0043984	histone H4-K16 acetylation	20018852

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:44044591/chr20:34487292)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PTPRF (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PHF20 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000359947

PTPRF

chr1

44044591

ENST00000374012

PHF20

chr20

34487292

5530

1019

310

2775

821

ENST00000438120

PTPRF

chr1

44044591

ENST00000374012

PHF20

chr20

34487292

5516

1005

296

2761

821

ENST00000372413

PTPRF

chr1

44044591

ENST00000374012

PHF20

chr20

34487292

5236

725

2481

821

ENST00000372414

PTPRF

chr1

44044591

ENST00000374012

PHF20

chr20

34487292

5236

725

2481

821

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000359947	ENST00000374012	PTPRF	chr1	44044591	+	PHF20	chr20	34487292	+	0.002027788	0.9979722
ENST00000438120	ENST00000374012	PTPRF	chr1	44044591	+	PHF20	chr20	34487292	+	0.002027485	0.99797255
ENST00000372413	ENST00000374012	PTPRF	chr1	44044591	+	PHF20	chr20	34487292	+	0.001449678	0.99855036
ENST00000372414	ENST00000374012	PTPRF	chr1	44044591	+	PHF20	chr20	34487292	+	0.001449678	0.99855036

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PTPRF-PHF20

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PTPRF	chr1	44044591	PHF20	chr20	34487292	1005	236	GTRYSAPANLYVRVTNTFKKTDDFGS
PTPRF	chr1	44044591	PHF20	chr20	34487292	1019	236	GTRYSAPANLYVRVTNTFKKTDDFGS
PTPRF	chr1	44044591	PHF20	chr20	34487292	725	236	GTRYSAPANLYVRVTNTFKKTDDFGS

Top

Potential FusionNeoAntigen Information of PTPRF-PHF20 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PTPRF-PHF20_44044591_34487292.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B15:02	YVRVTNTF	0.9704	0.9468	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B27:05	VRVTNTFKK	0.9991	0.856	11	20
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-A30:08	YVRVTNTFK	0.9879	0.7697	10	19
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B08:09	NLYVRVTNT	0.984	0.7565	8	17
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B15:18	LYVRVTNTF	0.332	0.7785	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-A24:14	ANLYVRVTNTF	0.9358	0.572	7	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C12:12	YVRVTNTF	0.9903	0.863	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B27:14	VRVTNTFKK	0.9982	0.8083	11	20
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B27:03	VRVTNTFKK	0.9696	0.8775	11	20
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B07:12	APANLYVRV	0.9236	0.603	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B51:07	APANLYVRV	0.8757	0.7554	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B15:21	LYVRVTNTF	0.7434	0.9368	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B42:02	APANLYVRV	0.7134	0.7752	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B42:01	APANLYVRV	0.6568	0.7661	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:19	LYVRVTNTF	0.5238	0.5642	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:80	LYVRVTNTF	0.4448	0.9122	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:67	LYVRVTNTF	0.4448	0.9122	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:05	LYVRVTNTF	0.4424	0.9432	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C12:16	LYVRVTNTF	0.4415	0.9699	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:10	LYVRVTNTF	0.4313	0.9261	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:29	LYVRVTNTF	0.4039	0.9348	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:27	LYVRVTNTF	0.4037	0.9388	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B39:10	APANLYVRV	0.3966	0.9402	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:46	LYVRVTNTF	0.3648	0.7842	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B15:11	YVRVTNTF	0.9973	0.9023	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B15:08	YVRVTNTF	0.9973	0.9063	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C03:02	YVRVTNTF	0.9972	0.9682	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C12:02	YVRVTNTF	0.9933	0.9548	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C02:10	YVRVTNTF	0.9721	0.9812	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C02:02	YVRVTNTF	0.9721	0.9812	10	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B27:10	VRVTNTFKK	0.9988	0.8559	11	20
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-A30:01	YVRVTNTFK	0.9874	0.8467	10	19
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B78:02	APANLYVRV	0.9151	0.6247	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-B67:01	APANLYVRV	0.6447	0.8213	5	14
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:17	LYVRVTNTF	0.5245	0.9686	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C03:67	LYVRVTNTF	0.4742	0.9853	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C07:02	LYVRVTNTF	0.4448	0.9122	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C14:03	LYVRVTNTF	0.1352	0.9523	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C14:02	LYVRVTNTF	0.1352	0.9523	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C06:06	LYVRVTNTF	0.0284	0.9879	9	18
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	HLA-C04:04	LYVRVTNTF	0.0101	0.8252	9	18

Top

Potential FusionNeoAntigen Information of PTPRF-PHF20 in HLA II

PTPRF-PHF20_44044591_34487292.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0101	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0101	PANLYVRVTNTFKKT	6	21
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0101	NLYVRVTNTFKKTDD	8	23
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0102	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0103	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0104	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0104	NLYVRVTNTFKKTDD	8	23
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0104	PANLYVRVTNTFKKT	6	21
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0105	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0105	PANLYVRVTNTFKKT	6	21
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0105	NLYVRVTNTFKKTDD	8	23
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0106	NLYVRVTNTFKKTDD	8	23
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0108N	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0111	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0112	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0113	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0113	PANLYVRVTNTFKKT	6	21
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0113	NLYVRVTNTFKKTDD	8	23
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0114	ANLYVRVTNTFKKTD	7	22
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0114	PANLYVRVTNTFKKT	6	21
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0114	NLYVRVTNTFKKTDD	8	23
PTPRF-PHF20	chr1	44044591	chr20	34487292	1019	DRB5-0203	ANLYVRVTNTFKKTD	7	22

Top

Fusion breakpoint peptide structures of PTPRF-PHF20

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6494	PANLYVRVTNTFKK	PTPRF	PHF20	chr1	44044591	chr20	34487292	1019

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PTPRF-PHF20

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	6494	PANLYVRVTNTFKK	-7.9962	-8.1096
HLA-B14:02	3BVN	6494	PANLYVRVTNTFKK	-5.70842	-6.74372
HLA-B52:01	3W39	6494	PANLYVRVTNTFKK	-6.83737	-6.95077
HLA-B52:01	3W39	6494	PANLYVRVTNTFKK	-4.4836	-5.5189
HLA-A11:01	4UQ2	6494	PANLYVRVTNTFKK	-10.0067	-10.1201
HLA-A11:01	4UQ2	6494	PANLYVRVTNTFKK	-9.03915	-10.0745
HLA-A24:02	5HGA	6494	PANLYVRVTNTFKK	-6.56204	-6.67544
HLA-A24:02	5HGA	6494	PANLYVRVTNTFKK	-5.42271	-6.45801
HLA-B44:05	3DX8	6494	PANLYVRVTNTFKK	-7.85648	-8.89178
HLA-B44:05	3DX8	6494	PANLYVRVTNTFKK	-5.3978	-5.5112
HLA-A02:01	6TDR	6494	PANLYVRVTNTFKK	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PTPRF-PHF20

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PTPRF-PHF20	chr1	44044591	chr20	34487292	10	18	YVRVTNTF	ATGTGCGAGTAACAAATACTTTTA
PTPRF-PHF20	chr1	44044591	chr20	34487292	10	19	YVRVTNTFK	ATGTGCGAGTAACAAATACTTTTAAGA
PTPRF-PHF20	chr1	44044591	chr20	34487292	11	20	VRVTNTFKK	TGCGAGTAACAAATACTTTTAAGAAAA
PTPRF-PHF20	chr1	44044591	chr20	34487292	5	14	APANLYVRV	CCCCTGCGAACCTGTATGTGCGAGTAA
PTPRF-PHF20	chr1	44044591	chr20	34487292	7	18	ANLYVRVTNTF	CGAACCTGTATGTGCGAGTAACAAATACTTTTA
PTPRF-PHF20	chr1	44044591	chr20	34487292	8	17	NLYVRVTNT	ACCTGTATGTGCGAGTAACAAATACTT
PTPRF-PHF20	chr1	44044591	chr20	34487292	9	18	LYVRVTNTF	TGTATGTGCGAGTAACAAATACTTTTA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
PTPRF-PHF20	chr1	44044591	chr20	34487292	6	21	PANLYVRVTNTFKKT	CTGCGAACCTGTATGTGCGAGTAACAAATACTTTTAAGAAAACAG
PTPRF-PHF20	chr1	44044591	chr20	34487292	7	22	ANLYVRVTNTFKKTD	CGAACCTGTATGTGCGAGTAACAAATACTTTTAAGAAAACAGATG
PTPRF-PHF20	chr1	44044591	chr20	34487292	8	23	NLYVRVTNTFKKTDD	ACCTGTATGTGCGAGTAACAAATACTTTTAAGAAAACAGATGATT

Top

Information of the samples that have these potential fusion neoantigens of PTPRF-PHF20

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
OV	PTPRF-PHF20	chr1	44044591	ENST00000359947	chr20	34487292	ENST00000374012	TCGA-61-2111-01A

Top

Potential target of CAR-T therapy development for PTPRF-PHF20

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PTPRF-PHF20

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PTPRF-PHF20

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)